In the EMILIA trial, upon which the FDA approval was based, T-DM1 demonstrated significant clinical efficacy (higher PFS and OS) and lessened toxicity in comparison to lapatinib plus capecitabine, a standard of care, in HER2+ BC patients exhibiting disease progression with trastuzumab and a taxane [60]. The gene discussed is ERBB2; the disease is breast cancer.